Skip to content
Review Open access

The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy

Sep 2026 · Life · Vol 16 · 0 citations · 152 references
Medicine

TL;DR

Evidence that agents capable of inducing ICD may instead promote cellular senescence when administered at lower concentrations for prolonged periods is highlighted, indicating that these distinct cellular outcomes can be determined by drug dose and treatment duration.

Abstract

Despite rapid advances in anticancer therapy, cancer incidence and mortality remain substantial worldwide. Although immune checkpoint inhibitors (ICIs), including anti-PD-1/PD-L1 and anti-CTLA-4 therapies, have transformed cancer treatment by harnessing host antitumor immunity, their efficacy remains limited to a subset of patients, largely because of the complexity of the tumor microenvironment. This review examines drug-induced immunogenic cell death (ICD) and drug-induced senescence as complementary strategies for overcoming these limitations and enhancing immunotherapeutic responses. We further highlight evidence that agents capable of inducing ICD may instead promote cellular senescence when administered at lower concentrations for prolonged periods, indicating that these distinct cellular outcomes can be determined by drug dose and treatment duration. This dose- and time-dependent relationship suggests that the therapeutic application of the same agent may require optimization according to the patient’s condition and tumor stage. Collectively, this review provides an integrated perspective on the selective use of ICD and senescence induction to enhance antitumor immunity, improve therapeutic outcomes, and potentiate synergistic responses to existing ICIs.

Read PDF

Similar papers

Review Open access Sep 2026

Adoptive cell therapy in lung cancer: progress, challenges, and prospects

Lung cancer is the leading cause of cancer-related deaths worldwide. Over the past decade, immunotherapy, represented by immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) or cytotoxic T lymphocyte associated antigen-4 (CTLA-4), has revoluti...

Jing-Yi Li, Chan Tong, Yong-Chang Chen et al. · 0 citations
Oct 2026

Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment.

Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.

Y. Senent, R. Manguso · 0 citations
Review Open access Oct 2026

Overcoming adaptive resistance to cancer immunotherapy: molecular targeting strategies for the tumor microenvironment

ABSTRACT Introduction Immunotherapy resistance is mediated by mechanisms distinct from those underlying conventional chemotherapy, including tumor-intrinsic alterations, an immunosuppressive tumor microenvironment, and other host factors, that collectively constrain durable responses. Areas covered This review provides...

Kenneth K. W. To, Ting-Nan Ma, Long-Ling Wang et al. · 0 citations
Review Open access Sep 2026

The evolving role of immunotherapy in ovarian cancer

Research directions to make ovarian cancer more susceptible to immunotherapy are moving from empiric treatment to more biologically informed, multimodal approaches aimed at overcoming immune suppression, enhancing antitumor immunity, and personalizing treatment for patients with ovarian cancer.

A. Veneziani, Laura Venegas, A. Oza · 0 citations
Review Open access Sep 2026

Therapeutic vaccines for NSCLC: From mechanisms to clinical translation

Despite advances in targeted therapy and immune checkpoint inhibitors (ICIs), durable disease control remains elusive for most patients with non-small cell lung cancer (NSCLC), particularly those with advanced-stage disease. Therapeutic cancer vaccines offer the potential for sustained immune surveillance by inducing t...

Wei-Jing Liu, Jie-Fei Han, K. Fei et al. · 4 citations
Sep 2026

Senolytic Interventions Enhance the Anti-metastatic Activity of Chemotherapy in Prostate Cancer.

Cellular senescence is a common outcome of cytostatic and cytotoxic cancer therapies. While in some contexts therapy-induced senescence can drive tumor growth suppression and anti-tumor immunity through the senescence-associated secretory phenotype (SASP), in others it can promote metastatic progression and immune supp...

Lin Zhou, Katherine C. Murphy, Hadiya K. Giwa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.